FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

2.

A Lot Can Be Said About You by Including Yourself in Photos.

3.

Immunotherapy after surgery is good for patients with advanced cancer

4.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

5.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot